修复而非旁路:耳畸蛋白基因治疗与听力损失治疗新纪元
FDA批准基于AAV的Otarmeni基因治疗用于双等位OTOF相关感音神经性听力损失,标志耳科从旁路 defective 听觉生理转向修复。早期临床试验中75%可评估受试者在24周达到主要听力终点,但长期耐久性、再给药及手术物流仍待解决。
要点
- OTOF基因替代靶向结构完整耳蜗的突触缺陷,区别于人工耳蜗的旁路机制。
- 早期试验中75%可评估受试者在24周达到主要听力终点。
- 主张建立「生物学允许时修复、不允许时旁路」的新治疗层级。
核心结论
- 耳畸蛋白基因治疗开启新治疗层级,而非淘汰人工耳蜗。
研究设计与样本
- 本文为评论文章,基于FDA批准Otarmeni(AAV基因治疗)及早期临床试验数据。
主要发现
- 早期临床试验中75%可评估受试者(分子确诊双等位OTOF变异儿童)在24周达到主要听力终点。
关键数值与推荐
- 双等位OTOF相关感音神经性听力损失为Otarmeni适应症。
- 主要听力终点评估时间为24周。
临床怎么用
- 生物学允许时修复,不允许时旁路。
- 需推进新生儿基因筛查、人员培训及公平可及的基因递送。
局限性
- 长期耐久性、再给药可行性及耳蜗内递送的手术与物流基础设施尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The FDA approval of Otarmeni, an AAV-based gene therapy for biallelic OTOF-associated sensorineural hearing loss, represents a conceptual shift in otology: from bypassing defective auditory physiology to restoring it. Unlike cochlear implantation, which circumvents damaged sensory structures, OTOF gene replacement targets a synaptic deficit in a structurally intact cochlea. Early clinical trial data are encouraging, with 75% of evaluable participants-children with molecularly confirmed biallelic OTOF variants enrolled in early-phase trials-achieving the primary hearing endpoint at 24 weeks. However, critical questions remain regarding long-term durability, the feasibility of redosing, and the surgical and logistical infrastructure required for intracochlear delivery. This commentary argues that otoferlin gene therapy initiates a new treatment hierarchy rather than rendering cochlear implantation obsolete: restore when biology permits, bypass when it does not. Realizing this potential will require advances in newborn genetic screening, workforce training, and equitable access to gene delivery.
引用
- Selvasingh JA, Shinn JR. Restoration, Not Bypass: Otoferlin Gene Therapy and a New Era in Hearing Loss Treatment. Otolaryngol Head Neck Surg. 2026. PMID: 42470357. doi:10.1002/ohn.70347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。